5-year results from the pivotal WATER trial showed IPSS improvement was greater with Aquablation compared with TURP. Aquablation therapy demonstrated strong efficacy and safety vs transurethral ...

New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA. In this episode, ‘Comparative PSMA PET Tracer ...

Leflutrozole, an aromatase inhibitor, is being tested in a phase 2 trial for male infertility due to low testosterone levels. The trial will enroll 200 patients, assessing leflutrozole's impact on ...

The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...

Pasritamig targets KLK2 and has FDA fast track designation for mCRPC, enabling accelerated development and review processes. Phase 1 study showed pasritamig was well-tolerated with promising antitumor ...

Pembrolizumab plus axitinib showed superior overall survival and progression-free survival compared to sunitinib in advanced clear cell renal cell carcinoma. The combination therapy demonstrated a ...

The updated guideline emphasizes a patient-centered, risk-based approach, prioritizing symptom resolution and antimicrobial stewardship over microbial eradication. New recommendations include ...

"This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters, so that more physicians and patients can benefit from this ...

Advances in laser technology, morcellator design, and anesthetic approach have substantially improved HoLEP efficiency and patient recovery over the past decade, while surgeon-owned procedural ...

Clinical research has demonstrated a 10-minute onset interval for the topical gel formulation MED3000, compared to an interval of at least 30 minutes with PDE5 inhibitors, such as Cialis and Viagra.

CPT 51798 will not be paid if performed in place of service 21 or 23, according to Jonathan Rubenstein, and Mark Painter. I need some guidance on billing for the bladder scan procedure (51798). As it ...

The CaverSTIM device demonstrated safety and feasibility in a first-in-man study, with 9 out of 10 patients regaining potency post-RARP. The study reported no device-related infections or pain, and ...